Surgical management of patients with persistent or recurrent medullary thyroid cancer
Residual or recurrent medullary thyroid carcinoma (MTC), manifested by elevated calcitonin levels, occurs commonly following primary treatment of MTC. Re-operation in appropriately selected patients is the only treatment modality which consistently and reliably reduces stimulated calcitonin levels, and results in excellent local disease control. We report improved results of surgical management of recurrent MTC in two consecutive series of patients. In our most recent series (1992-96), 38% of patients (17 out of 45) had normal postoperative stimulated calcitonin levels, compared to 28% (nine of 32) in our first series (1990-92). In the most recent series, only 13% (six of 45) of patients had no decrease in calcitonin levels following re-operation, compared to 31% (10 of 32) in our first series (P = 0.07, Fisher's exact test). This improvement has mainly occurred through better preoperative selection of patients, and the institution of routine laparoscopic liver examination preoperatively, which identified metastases in 10 patients, nine of whom had normal CT or MRI imaging.
Management of occult medullary thyroid carcinoma: evidenced only by serum calcitonin level elevations after apparently adequate neck operations
Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma
Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications
Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer
Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results
Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer
Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors
Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.
The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form
Great cervical venous tumoral thrombosis of melanotic medullary carcinoma thyroid: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography enabled diagnosis and radiotherapy planning
Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging
Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years
Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment-oriented surgery
Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements
A unique combination of pre- and intraoperative modalities for the diagnosis and localization of recurrent medullary thyroid carcinoma
Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism
Autoimmune Polyendocrine Syndromes
This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.